Amphastar Pharmaceuticals - AMPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $66.00
  • Forecasted Upside: 70.54%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$38.70
▼ -0.47 (-1.20%)

This chart shows the closing price for AMPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amphastar Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMPH

Analyst Price Target is $66.00
▲ +70.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $66.00, with a high forecast of $71.00 and a low forecast of $60.00. The average price target represents a 70.54% upside from the last price of $38.70.

This chart shows the closing price for AMPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Amphastar Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$71.00 ➝ $71.00Low
5/22/2024Needham & Company LLCReiterated RatingHoldLow
5/9/2024Needham & Company LLCReiterated RatingHoldLow
4/10/2024Needham & Company LLCReiterated RatingHoldLow
3/5/2024JPMorgan Chase & Co.Initiated CoverageOverweight$60.00Low
11/17/2023Bank of AmericaInitiated CoverageNeutral$63.00Low
8/9/2023Piper SandlerBoost Target$66.00 ➝ $71.00Low
7/25/2023Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$70.00Low
7/18/2023Piper SandlerBoost Target$55.00 ➝ $66.00Low
6/15/2023Piper SandlerBoost Target$43.00 ➝ $55.00Low
10/25/2022Piper SandlerLower TargetOverweight$43.00 ➝ $40.00Low
10/21/2022Jefferies Financial GroupDowngradeBuy$36.00Low
7/29/2022Capital One FinancialInitiated CoverageOverweight$44.00Low
4/11/2022Northland SecuritiesBoost Target$33.00 ➝ $43.00Medium
3/15/2022Wells Fargo & CompanyBoost TargetEqual Weight$23.00 ➝ $32.00Low
3/11/2022Piper SandlerBoost TargetOverweight$28.00 ➝ $35.00High
1/7/2022Piper SandlerUpgradeNeutral ➝ Overweight$21.00 ➝ $28.00High
7/20/2021Northland SecuritiesReiterated RatingBuy$23.00Medium
3/17/2021Wells Fargo & CompanyLower TargetEqual Weight$21.00 ➝ $20.00Medium
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$21.00High
10/5/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$24.00High
8/7/2020Northland SecuritiesReiterated RatingHold$23.00High
7/9/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$23.00High
6/10/2020Needham & Company LLCReiterated RatingHoldMedium
6/8/2020Northland SecuritiesReiterated RatingBuy$23.00Medium
5/14/2020Northland SecuritiesReiterated RatingBuy$23.00High
5/11/2020BMO Capital MarketsBoost TargetMarket Perform$20.00 ➝ $21.00High
5/7/2020Northland SecuritiesReiterated RatingBuyMedium
5/1/2020Northland SecuritiesInitiated CoverageOutperform$23.00Low
4/27/2020Needham & Company LLCReiterated RatingHoldLow
1/29/2020Needham & Company LLCReiterated RatingHoldHigh
(Data available from 7/15/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/16/2024
  • 18 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/17/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/16/2024
  • 16 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/16/2024
  • 17 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/15/2024
  • 10 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 10 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $38.70
Low: $38.40
High: $39.86

50 Day Range

MA: $40.94
Low: $36.99
High: $43.48

52 Week Range

Now: $38.70
Low: $36.56
High: $67.66

Volume

374,500 shs

Average Volume

420,514 shs

Market Capitalization

$1.89 billion

P/E Ratio

13.39

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Amphastar Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Amphastar Pharmaceuticals in the last twelve months: Bank of America Co., Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, and StockNews.com.
View the latest analyst ratings for AMPH.

What is the current price target for Amphastar Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Amphastar Pharmaceuticals in the last year. Their average twelve-month price target is $66.00, suggesting a possible upside of 70.5%. Piper Sandler has the highest price target set, predicting AMPH will reach $71.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $60.00 for Amphastar Pharmaceuticals in the next year.
View the latest price targets for AMPH.

What is the current consensus analyst rating for Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMPH.

What other companies compete with Amphastar Pharmaceuticals?

How do I contact Amphastar Pharmaceuticals' investor relations team?

Amphastar Pharmaceuticals' physical mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company's listed phone number is (909) 980-9484 and its investor relations email address is [email protected]. The official website for Amphastar Pharmaceuticals is www.amphastar.com. Learn More about contacing Amphastar Pharmaceuticals investor relations.